Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from PhRMA

19:00 EDT 16th September 2019 | BioPortfolio

Here are the most relevant search results for "PhRMA" found in our extensive news archives from over 250 global news sources.

More Information about PhRMA on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about PhRMA for you to read. Along with our medical data and news we also list PhRMA Clinical Trials, which are updated daily. BioPortfolio also has a large database of PhRMA Companies for you to search.

Showing News Articles 1–25 of 631 from PhRMA

Friday 13th September 2019

IP Explained: Four things to know about the Bayh-Dole Act

Thanks in large part to strong intellectual property protections – including policies that incentivize public and private investments in research and development (R&D) – the United States is the global leader in biopharmaceutical innovation. We’ve previously examined how the public and private sectors play complimentary roles with the biopharmaceutical

Thursday 12th September 2019

I enjoyed touring the Rx Abuse Leadership Initiative, @WeAreCode3 & @PhRMA trailer this morning, where law enforcement officers pointed out warning signs of drug misuse in a mock teenager’s room. This trailer is just one way we are working to solve the

I enjoyed touring the Rx Abuse Leadership Initiative, @WeAreCode3 & @PhRMA trailer this morning, where law enforcement officers pointed out warning signs of drug misuse in a mock teenager’s room. This trailer is just one way we are working to solve the opioid crisis. pic.twitter.com/zfX9YtdsHj

Tuesday 10th September 2019

A new study from the Partnership for Health Analytic Research shows that hospitals make 9 times more than physicians’ offices on provider-administered medicines, driving up costs for everyone https://catalyst.phrma.org/hospitals-make-9-times-more-than-

A new study from the Partnership for Health Analytic Research shows that hospitals make 9 times more than physicians’ offices on provider-administered medicines, driving up costs for everyone https://catalyst.phrma.org/hospitals-make-9-times-more-than-physicians-offices-on-provider-administered-medicines … pic.twitter.com/3N7YBOmuw5

Hospitals make 9 times more than physicians’ offices on provider-administered medicines

A new study, conducted by the Partnership for Health Analytic Research (PHAR), found that hospitals retained 91% of the total profit on physician-administered medicines in the commercial market that went to providers in 2016. The data also show that physicians retained just 9%, even though they treated a nearly equal number of patients. This further demonstrates

Monday 9th September 2019

No surprise: @UnitedHealthGrp $UHC admits that #hospitals raise #drug spending by overcharging vs. other sites of care. How about site-neutral #drug payments and better network management? https://drugch.nl/2LBpJg9  P.S. This is why "drug spending"

No surprise: @UnitedHealthGrp $UHC admits that #hospitals raise #drug spending by overcharging vs. other sites of care. How about site-neutral #drug payments and better network management? https://drugch.nl/2LBpJg9  P.S. This is why "

Thursday 5th September 2019

Hospitals represent the largest chunk of U.S. health care spending. And hospitals are acquiring more market power and commanding higher prices — bills that every American pays for in some part. https://www.axios.com/newsletters/axios-vitals-f15932e5-dea

Hospitals represent the largest chunk of U.S. health care spending. And hospitals are acquiring more market power and commanding higher prices — bills that every American pays for in some part. https://www.axios.com/newsletters/axios-vitals-f15932e5-dea2-4daa-934b-e21da87ecfc2.html?chunk=0&utm_term=emshare#story0 …

Wednesday 4th September 2019

Glad @TiffanyHaverly was able to join your show. If your listeners have any question or would like to learn more about our medicine assistance tool, visit https://mat.org/ . Keep up the awesome work, Roxanne!https://twitter.com/roxannewatson74/status/11

Glad @TiffanyHaverly was able to join your show. If your listeners have any question or would like to learn more about our medicine assistance tool, visit https://mat.org/ . Keep up the awesome work, Roxanne! https://twitter.com/roxannewatson74/status/1169322086675951616 …

I am excited to welcome Giovanni Caforio, CEO of @bmsnews, as @PhRMA's new board chairman. Giovanni's proven record of leadership and his commitment to improving patient access and affordability will help us advance reforms that lower out-of-pockets costs

I am excited to welcome Giovanni Caforio, CEO of @bmsnews, as @PhRMA's new board chairman. Giovanni's proven record of leadership and his commitment to improving patient access and affordability will help us advance reforms that lower out-of-pockets costs: https://phrma.org/Press-Release/Bristol-Myers-Squibb-CEO-Giovanni-Caforio-Becomes-PhRMA-Board-Chairman …

Helping change the course of disease drives biopharmaceutical researchers like Craig at @Novartis to continue working for new breakthroughs and personalized therapies like CAR-T to treat today’s illnesses. Learn more: http://bit.ly/2HMXPfT  #GoBoldlyp

Helping change the course of disease drives biopharmaceutical researchers like Craig at @Novartis to continue working for new breakthroughs and personalized therapies like CAR-T to treat today’s illnesses. Learn more: http://bit.ly/2HMXPfT  #GoBoldly pic.twitter.com/K1SJYtv2yH

Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less ...

Monday 2nd September 2019

My “Op-Ed” in today’s Boston Globe tells how drug invention really works: academic and industry res. are essential. The notion that govt-funded res. creates drugs while BioPharma simply manufacturers is incorrect and could lead to misdirected policy

My “Op-Ed” in today’s Boston Globe tells how drug invention really works: academic and industry res. are essential. The notion that govt-funded res. creates drugs while BioPharma simply manufacturers is incorrect and could lead to misdirected policy. https://www.bostonglobe.com/opinion/2019/09/02/biopharmaceutical-companies-aren-free-riding-government-research/il6C9uPEP73Klkx6DJ...

Wednesday 28th August 2019

Competition from biosimilars is restraining costs and improving patient affordability. As I noted in my response to a recent @WSJOpinion piece, throwing in the towel on this new category of medicines would be shortsighted https://www.wsj.com/articles/we-n

Competition from biosimilars is restraining costs and improving patient affordability. As I noted in my response to a recent @WSJOpinion piece, throwing in the towel on this new category of medicines would be shortsighted https://www.wsj.com/articles/we-need-a-more-rational-biosimilars-policy-11566934161 …

Tuesday 27th August 2019

IP Explained: Three forms of IP protections for medicines

Intellectual property (IP) protections for the biopharmaceutical sector provide incentives that help to promote the discovery and development of life-saving medicines for patients and foster a competitive market for generic and biosimilar medicines. There are three forms of IP protections critical to biopharmaceutical development, and although they work toge

Monday 26th August 2019

Three reasons the Senate Finance package is the wrong approach for patients https://catalyst.phrma.org/three-reasons-the-senate-finance-package-is-the-wrong-approach-for-patients …

Three reasons the Senate Finance package is the wrong approach for patients https://catalyst.phrma.org/three-reasons-the-senate-finance-package-is-the-wrong-approach-for-patients …

Pfizer’s $500M investment in Sanford highlights NC’s growth in gene therapy https://www.newsobserver.com/news/business/article234276912.html …

Pfizer’s $500M investment in Sanford highlights NC’s growth in gene therapy https://www.newsobserver.com/news/business/article234276912.html …

Three reasons the Senate Finance package is the wrong approach for patients

For more than a decade, Medicare Part D has successfully provided seniors and people with disabilities comprehensive prescription drug coverage, while its unique market-based structure has kept overall program costs far below initial projections. In fact, according to a new nationwide survey, nearly nine of ten seniors are satis

Thursday 22nd August 2019

Did you know that hospitals are the primary drivers of health care spending? Conversations about health care spending need to look at the whole system. Read more: https://catalyst.phrma.org/fact-check-how-hospitals-continue-to-drive-health-care-spending 

Did you know that hospitals are the primary drivers of health care spending? Conversations about health care spending need to look at the whole system. Read more: https://catalyst.phrma.org/fact-check-how-hospitals-continue-to-drive-health-care-spending …

#DYK our very own researchers and labs in Massachusetts were featured in @PhRMA’s latest #GoBoldly video? We’re proud to represent the industry and medical innovation. Watch Breakthrough here: http://bit.ly/2ZlPZzU pic.twitter.com/zXvi3gvs0a

#DYK our very own researchers and labs in Massachusetts were featured in @PhRMA’s latest #GoBoldly video? We’re proud to represent the industry and medical innovation. Watch Breakthrough here: http://bit.ly/2ZlPZzU  pic.twitter.com/zXvi3gvs0a

Wednesday 21st August 2019

Fact Check: How hospitals continue to drive health care spending

There is a lot of talk about health care costs in the United States that is mostly centered on prescription medicine spending, overlooking the largest share of U.S. health care spending – hospital care. And hospital spending continues to grow as their prices increase.

Tuesday 20th August 2019

A hospital charged over $2800 for a rabies medicine that costs $350 at the pharmacy. Medicines don’t perform 8x better at the hospital, so why are patients billed 8x more? https://khn.org/news/a-brush-with-a-notorious-cat-my-rabies-education-and-the-big

A hospital charged over $2800 for a rabies medicine that costs $350 at the pharmacy. Medicines don’t perform 8x better at the hospital, so why are patients billed 8x more? https://khn.org/news/a-brush-with-a-notorious-cat-my-rabies-education-and-the-big-bill-that-followed/ …

DYK that on top of the increasing role of retail pharmacies, specialty pharmacies owned by PBMs have also started aggressively contracting with 340B hospitals for their own financial benefit? https://catalyst.phrma.org/340b-spotlight-how-for-profit-middle

DYK that on top of the increasing role of retail pharmacies, specialty pharmacies owned by PBMs have also started aggressively contracting with 340B hospitals for their own financial benefit? https://catalyst.phrma.org/340b-spotlight-how-for-profit-middlemen-are-taking-advantage-of-a-program-meant-to-support-nonprofit-entities-and-patients …

340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients

Congress created the 340B program to help safety-net providers, like federally-funded safety net clinics, access discounts on prescription medicines for vulnerable or uninsured patients. Unfortunately, many for-profit pharmacies and other third parties are taking advantage of the program by capturing some of these significant 340B discounts.

New analysis highlights how government intervention in Part B could threaten patient access to medicines https://catalyst.phrma.org/new-analysis-government-intervention-in-part-b-threatens-patient-access-to-medicines …

New analysis highlights how government intervention in Part B could threaten patient access to medicines https://catalyst.phrma.org/new-analysis-government-intervention-in-part-b-threatens-patient-access-to-medicines …

Monday 19th August 2019

New analysis: Government intervention in Part B threatens patient access to medicines

A new analysis from Avalere looked at how access to medicines in Part B may be impacted if the government only covered a certain list of medicines, an approach known as applying a national formulary. Unlike Medicare, the U.S. Department of Veterans Affairs (VA) uses a national formulary, and Avalere compared coverage for physician-administered medicines available to veterans through th...

Friday 16th August 2019

Regardless of whether PBMs pass through rebates to insurers, the bottom line is that they aren’t being used to lower patients costs at the pharmacy counter. Read more: https://catalyst.phrma.org/three-things-to-know-about-the-part-d-gao-report …

Regardless of whether PBMs pass through rebates to insurers, the bottom line is that they aren’t being used to lower patients costs at the pharmacy counter. Read more: https://catalyst.phrma.org/three-things-to-know-about-the-part-d-gao-report …


Quick Search

News Quicklinks